UFPT UFP TECHNOLOGIES INC
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 914156 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY8.6%
TTM net income YoY14.0%
TTM EPS YoY13.7%
Revenue 3-yr CAGR18.6%
Net income 3-yr CAGR22.4%
Margins
Gross margin28.9%
Operating margin15.5%
Net margin11.8%
FCF margin—
EBITDA margin18.5%
Returns
ROE17.2%
ROA11.5%
ROIC (approx.)15.0%
Asset turnover0.97x
Leverage & solvency
Liabilities / assets28.8%
Debt / equity0.20x
Current ratio2.98x
Interest coverage14.64x
Cash quality & payout
Operating cash flow / net income0.97x
Accruals ratio0.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $602.80M | $504.42M |
| Cost of revenue | $432.39M | $357.73M |
| Gross profit | $170.41M | $146.69M |
| R&D expense | $8.60M | $10.40M |
| SG&A expense | $77.44M | $62.22M |
| Operating income | $92.34M | $80.90M |
| Interest expense | $9.80M | $8.06M |
| Pretax income | $82.51M | $73.03M |
| Income tax | $14.20M | $14.04M |
| Net income | $68.31M | $58.98M |
| EBITDA | $111.49M | $95.61M |
| EPS (basic) | 8.87 | 7.69 |
| EPS (diluted) | 8.75 | 7.58 |
| Weighted avg. shares (diluted) | 7.80M | 7.79M |
| Balance sheet | ||
| Cash & equivalents | $20.30M | $13.45M |
| Receivables | $82.91M | $84.68M |
| Inventory | $86.86M | $87.54M |
| Current assets | $201.00M | $194.94M |
| PP&E, net | $79.11M | $70.56M |
| Goodwill | $197.40M | $189.66M |
| Intangibles | $140.85M | $144.25M |
| Total assets | $655.08M | $629.00M |
| Current liabilities | $74.86M | $76.30M |
| Short-term debt | $12.50M | $12.50M |
| Long-term debt | $122.95M | $176.88M |
| Total debt | $135.46M | $189.38M |
| Total liabilities | $231.20M | $286.24M |
| Shareholders' equity | $423.88M | $342.76M |
| Net debt | $115.15M | $175.93M |
| Shares outstanding | 7.71M | 7.68M |
| Cash flow statement | ||
| Operating cash flow | $91.91M | $66.59M |
| Capital expenditure | — | $9.66M |
| Free cash flow | — | $56.94M |
| Investing cash flow | -$27.60M | -$210.16M |
| Financing cash flow | -$58.16M | $152.39M |
| Depreciation & amortization | $19.15M | $14.71M |
| Stock-based compensation | $8.85M | $6.84M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.